243 related articles for article (PubMed ID: 30744321)
1. Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study.
Huang J; Chen X; Fei X; Huang O; Wu J; Zhu L; He J; Chen W; Li Y; Shen K
Cancer Res Treat; 2019 Oct; 51(4):1336-1346. PubMed ID: 30744321
[TBL] [Abstract][Full Text] [Related]
2. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M
Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
4. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
Kanou A; Masumoto N; Fukui K; Yokozaki M; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
J Med Ultrason (2001); 2022 Oct; 49(4):709-717. PubMed ID: 36002708
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
7. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
8. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.
Yoon CI; Park S; Cha YJ; Lee HS; Bae SJ; Cha C; Lee DY; Ahn SG; Jeong J
Breast; 2020 Apr; 50():141-148. PubMed ID: 31607527
[TBL] [Abstract][Full Text] [Related]
9. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
Cha YJ; Ahn SG; Bae SJ; Yoon CI; Seo J; Jung WH; Son EJ; Jeong J
Breast Cancer Res Treat; 2018 Sep; 171(2):295-302. PubMed ID: 29869774
[TBL] [Abstract][Full Text] [Related]
12. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis.
Ohtani H; Mori-Shiraishi K; Nakajima M; Ueki H
Pathol Int; 2015 Dec; 65(12):644-51. PubMed ID: 26530981
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
Tian T; Ruan M; Yang W; Shui R
Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
[TBL] [Abstract][Full Text] [Related]
14. No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014.
Park HS; Heo I; Kim JY; Kim S; Nam S; Park S; Kim SI
J Surg Oncol; 2016 Jul; 114(1):17-21. PubMed ID: 27157771
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
17. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
18. Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma.
Mutka M; Joensuu K; Heiskala M; Eray M; Heikkilä P
Virchows Arch; 2023 Aug; 483(2):215-224. PubMed ID: 37222841
[TBL] [Abstract][Full Text] [Related]
19. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
Kotoula V; Chatzopoulos K; Lakis S; Alexopoulou Z; Timotheadou E; Zagouri F; Pentheroudakis G; Gogas H; Galani E; Efstratiou I; Zaramboukas T; Koutras A; Aravantinos G; Samantas E; Psyrri A; Kourea H; Bobos M; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
Oncotarget; 2016 Jan; 7(4):5074-87. PubMed ID: 26506242
[TBL] [Abstract][Full Text] [Related]
20. Influences of preoperative metformin on immunological factors in early breast cancer.
Tsukioki T; Shien T; Tanaka T; Suzuki Y; Kajihara Y; Hatono M; Kawada K; Kochi M; Iwamoto T; Ikeda H; Taira N; Doihara H; Toyooka S
Cancer Chemother Pharmacol; 2020 Jul; 86(1):55-63. PubMed ID: 32533334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
